It's been a banner year for early-stage biotech stocks and we're barely into the second half. The iShares Biotechnology Index has risen an impressive 8.9% this year, but the market for small, early-stage biotech stocks is even frothier than the industry tracking index suggests.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,